15 research outputs found
Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats
No full text
Delayed Treatment Effects of Xanthine Oxidase Inhibition on Systolic Overload-Induced Left Ventricular Hypertrophy and Dysfunction
No full text
GENERATION OF RECTANGULAR BIPHASIC WAVEFORM TO DECREASE DEFIBRILLATION THRESHOLD FOR EXTERNAL DEFIBRILLATOR
No full textCardiac Output, Stroke Volume, and Pacing Rate: A Review of the Literature and a Proposed Technique for Selection of the Optimum Pacing Rate for an Exercise Responsive Pacemaker
No full textPharmacological Characterization of A-i 27722: An Orally Active and Highly Potent ETA-Selective Receptor Antagonist
No full textABSTRACT Endothelins (ET) are potent vasoactive peptides implicated i
Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 4. Side Chain Conformational Restriction Leads to ET B
No full text
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases
No full textOsteoblastic bone metastases are common in prostate and breast cancer patients, but mechanisms by which tumor cells stimulate new bone formation are unclear. We identified three breast cancer cell lines that cause osteoblastic metastases in a mouse model and secrete endothelin-1. Tumor-produced endothelin-1 stimulates new bone formation in vitro and osteoblastic metastases in vivo via the endothelin A receptor. Treatment with an orally active endothelin A receptor antagonist dramatically decreased bone metastases and tumor burden in mice inoculated with ZR-75-1 cells. Tumor-produced endothelin-1 may have a major role in the establishment of osteoblastic bone metastases, and endothelin A receptor blockade represents effective treatment
